Breast Cancer Research

CORRECTION Open Access

Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Jia Yu[1], Bo Qin[1,2], Ann M. Moyer[3], Jason P. Sinnwell[4], Kevin J. Thompson[4], John A. Copland III[5], Laura A. Marlow[5], James L. Miller[5], Ping Yin[2], Bowen Gao[13], Katherine Minter-Dykhouse[2], Xiaojia Tang[4], Sarah A. McLaughlin[6], Alvaro Moreno-Aspitia[7], Anthony Schweitzer[8], Yan Lu[8], Jason Hubbard[8], Donald W. Northfelt[9], Richard J. Gray[10], Katie Hunt[11], Amy L. Conners[11], Vera J. Suman[4], Krishna R. Kalari[4], James N. Ingle[2], Zhenkun Lou[2], Daniel W. Visscher[3], Richard Weinshilboum[1], Judy C. Boughey[12], Matthew P. Goetz[1,2] and Liewei Wang[1*]

Correction to: Breast Cancer Research 19, 130 (2017)
http://dx.doi.org/10.1186/s13058-017-0920-8

Following publication of the original article [1], the authors would like to correct several typos in the article text:

1) Page 4-right panel, Line 10: "The take rate was 51.3% (21/39; 95% CI: 34.8-67.6%) in TN subtype;". Take rate should be **20**/39 not 21/39. Percentages are correct.
2) Page 4-right panel, Line 21: The last 2 sentences were corrected to be consistent with Table 2 as follows: "There was no take among the 18 luminal tumors. However, five of nine TN, and one of the eight HER2+ post-chemotherapy residual tumors took (verified breast tumor)."
3) Page 4-right panel, Table 2: Total implanted for Luminal B should be **14** instead of 18. The total number of implanted 35 was correct.
4) Page 5-left panel, Line 15: HER2+ tumors (7/17 vs. 2/15) should be (7/**19** vs. 2/15). *P*-value is correct.
5) Page 5-left panel, Line 20, The number of luminal tumors should be 18 instead of 22.

The authors sincerely apologize for any inconvenience.

The original article can be found online at https://doi.org/10.1186/s13058-017-0920-8.

* Correspondence: Wang.Liewei@mayo.edu
[1]Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Full list of author information is available at the end of the article

Author details
[1]Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. [2]Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA. [3]Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA. [4]Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA. [5]Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA. [6]Department of Surgery, Mayo Clinic, Jacksonville, FL 32224, USA. [7]Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL 32224, USA. [8]Affymetrix, now part of Thermo Fisher Scientific, Santa Clara, CA 95051, USA. [9]Department of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA. [10]Department of Surgery, Mayo Clinic, Scottsdale, AZ 85259, USA. [11]Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. [12]Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.

[13]Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Published online: 25 March 2021

Reference

1. Yu, et al. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Research. 2017;19:130. https://doi.org/10.1186/s13058-017-0920-8.